Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

The .gov means it’s official.

Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.

The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

    CMS.gov Centers for Medicare & Medicaid Services CMS.gov Centers for Medicare & Medicaid Services opens in new window
    CMS.gov Centers for Medicare & Medicaid Services
    Centers for Medicare & Medicaid Services

    Main header

    • About Us
    • Newsroom
    • Data & Research
    MCD
    Medicare Coverage Database
    • Advanced Search
    • Indexes
    • Reports
    • Downloads
    • National Coverage
      • National Coverage Analyses (NCAs)
        • Open NCAs
        • Closed NCAs
      • Coding Analyses for Labs (CALs)
        • Closed CALs
      • National Coverage Determinations (NCDs)
        • NCDs Listed Alphabetically
        • NCDs by Chapter/Section
        • Lab NCDs
      • Meetings & Assessments
        • MEDCAC Meetings
        • Technology Assessments
      • Medicare Coverage Documents
        • CMS Solicitation of Public Comments.
        • Compendia
        • Expedited Process to Remove National Coverage Determinations
        • Guidance Documents
        • National Benefit Category Analyses
        • Potential National Coverage Determination (NCD) Topics
    • Local Coverage
      • Local Coverage Determinations (LCDs)
        • LCDs by Contractor
        • LCDs by State
        • LCDs Listed Alphabetically
      • Articles
        • Articles by Contractor
        • Articles by State
        • Articles Listed Alphabetically
      • Contacts
        • All Contacts Listed Alphabetically
        • Contacts for Part A - Medicare Administrative Contractor (MAC - Part A)
        • Contacts for Part B - Medicare Administrative Contractor (MAC - Part B)
        • Contacts for Durable Medical Equipment Medicare Administrative Contractor (DME MAC)
        • Contacts for Home Health & Hospice (HHH)
    • National Coverage
      • What's New Report
      • Annual Report
    • Local Coverage
      • What's New Report
      • LCD Status Report
      • Proposed LCD Status Report
      • LCD Last Updated Report
      • Article Status Report
      • SAD Exclusion List Report
    0
    • Help & Resources
    • Page Help opens in new window
    • Contact Us

    MCD

    View Public Comments for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers

    Use the selection criteria below to select the Comment Period for which you would like to view the comments for the selected document. You can use the alphabetical links above the results table to jump to comments submitted by a commenter whose last name starts with that letter. Select the 'Expand All Comments' link to view all the full comments, and click the 'Collapse All Comments' link to view only the abstract for all comments. Select the 'More' link in the Comment to view the full text of the specific comment in a new window.
    • Expand All All sections on the page are Expanded
    • Collapse All All sections on the page are Collapsed

    Collapse Public Comments Selection Criteria

    The first (earliest) set of comments are displayed by default in the Public Comment Results section. To view additional Comment Periods, use the radio button options and select the "Submit" button.
    An asterisk (*) indicates a required field.

          Select one period.


    RESET SELECTION CRITERIA

    Expand All Comments

    Collapse Public Comments Results

    [52 Comments]
    Selection Criteria:
    Comment Period: 05/16/2018-06/15/2018
    Select a link:
    Please Note: Only displaying linked letters for which there are records.
    • 0-9
    • A
    • B
    • C
    • D
    • E
    • F
    • G
    • H
    • I
    • J
    • K
    • L
    • M
    • N
    • O
    • P
    • Q
    • R
    • S
    • T
    • U
    • V
    • W
    • X
    • Y
    • Z
    Sort By:
    Page 1 of 3
    FirstPrev123NextLast
    First character of titleCommenterComment Information
    A
    Agha, Mounzer
    Title: MD
    Organization: UPMC, Hillman Cancer Center
    Date: 06/15/2018
    Comment:

    The new immunotherapy treatment CAR-T represent a paradigm change in cancer therapy. For the first time, cancer treatment can be directed specifically to the cancer cells, sparing most of the normal cells, and resulting in very high remission More opens in new window

    A
    Allen, Jeff
    Title: President and CEO
    Organization: Friends of Cancer Research
    Date: 06/15/2018
    Comment:

    Jeff Allen, PhD
    1800 M Street NW
    Suite 1050 South
    Washington, DC 20036

    June 15, 2018

    Tamara Syrek Jensen, JD
    Director, Coverage and Analysis Group
    Center for Clinical Standards and Quality
    Centers for More opens in new window

    A
    Arceo, Alex
    Title: Patient Access
    Organization: MDACC
    Date: 06/11/2018
    Comment:
    After two failed therapies, the patients are desperate for a life saving treatment, that is, the disease is so aggressive that there's a sense of urgency to save their lives. Considering this treatment as a covered benefit will help a lot of More opens in new window
    B
    Bagger, Richard
    Title: Executive Vice President
    Organization: Celgene Corporation
    Date: 06/15/2018
    Comment:

    Tamara Syrek Jensen
    Director, Evidence and Analysis Group
    Center for Clinical Standards and Quality
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    S3-02-01
    Baltimore, Maryland 21244 More opens in new window

    B
    Bankowitz, Richard
    Title: Chief Medical Officer
    Organization: America’s Health Insurance Plans (AHIP)
    Date: 06/14/2018
    Comment:

    America’s Health Insurance Plans (AHIP) appreciates the opportunity to comment on the national coverage analysis for CAR T-Cell Therapy for Cancers.

    We agree with the requestor that a national coverage determination may be useful for More opens in new window

    B
    Bartholemy, Ed
    Title: Board Member and Patient Caregiver
    Organization: MPN Research Foundation
    Date: 06/14/2018
    Comment:

    I urge that CAR T-cell therapy be covered by Medicare.

    CAR T therapy is a very promising approach to treating Primary Myleofibrosis, a disease [PHI Redacted] suffers from. She faces a likely choice in the next couple More opens in new window

    B
    Bens, Cynthia
    Title: Senior Vice President, Public Policy
    Organization: Personalized Medicine Coalition
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Tamara Syrek Jensen, J.D.
    Director, Coverage & Analysis Group
    Centers for Medicare & Medicaid Services
    Mailstop S3-02-01
    7500 Security Blvd.
    Baltimore, MD 21244

    Sent More opens in new window

    B
    Bernstetter, Steve
    Title: Director, Health Policy and Regulatory Compliance
    Organization: BJC HealthCare
    Date: 06/15/2018
    Comment:

    Thank you for this opportunity to comment on this National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell therapies. BJC HealthCare, our member teaching institution, Barnes-Jewish Hospital, and our physician partners at the More opens in new window

    B
    Bird, Karen
    Title: Executive Director
    Organization: Alliance of Dedicated Cancer Centers (ADCC)
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Ms. Seema Verma
    Administrator
    Centers for Medicare & Medicaid Services
    Department of Health and Human Services
    Hubert H. Humphrey Building
    Room 445-G
    200 Independence Avenue, NW
    Washington, More opens in new window

    B
    Brady, Leslie
    Title: Policy and Practice Manager
    Organization: American Society of Hematology
    Date: 06/14/2018
    Comment:

    June 15, 2018

    Tamara Syrek Jensen, JD, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    Katherine B. Szarama, PhD, Lead More opens in new window

    C
    Caligiuri, M.D., Michael
    Title: President & Physician-in-Chief
    Organization: City of Hope National Medical Center
    Date: 06/15/2018
    Comment:

    As the Physician-in-Chief at The City of Hope National Medical Center (COH), and the President of Strategy and Business Ventures, we welcome the opportunity to submit comments on behalf of our institution regarding the National Coverage Analysis More opens in new window

    C
    Carabasi, Matthew
    Title: Professor, Medical Oncology
    Organization: Sidney Kimmel Cancer Center Thomas Jefferson University
    Date: 06/15/2018
    Comment:

    June 15, 20018

    Re: National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)

    Dear Administrator Verma, Ms. Jensen and Drs. Szarama and Paserchia:

    The Sidney Kimmel Cancer Center More opens in new window

    C
    Carlson, Robert
    Title: Chief Executive Officer
    Organization: National Comprehensive Cancer Network
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Tamara Syrek Jensen, JD, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    RE: National Coverage Analysis (NCA) Tracking Sheet More opens in new window

    C
    College of American Pathologists, The
    Organization: College of American Pathologists
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Tamara Syrek Jensen, JD, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    Katherine B. Szarama, PhD, Lead Analyst
    Evidence More opens in new window

    C
    Currie, Alex
    Title: Director, Federal Relations
    Organization: Vanderbilt University Medical Center
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Tamara Syrek Jensen, JD, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    Katherine B. Szarama, PhD, Lead Analyst
    Evidence More opens in new window

    D
    Dolan, Mary
    Title: Senior Specialty Billing Analyst RN
    Organization: Piedmont Healthcare
    Date: 05/24/2018
    Comment:

    As a veteran of our country's health care system I endorse and support the approval of a National Coverage Determination for CAR T-cell Therapy for cancers where the clinical trial outcomes support such a therapy. My career spans over 45 years, More opens in new window

    E
    Essell, James
    Title: Chair Cellular Therapy
    Organization: The US Oncology Network
    Date: 06/15/2018
    Comment:

    Chimeric Antigen Receptor therapy (CAR-T) is a significant advancement in the treatment of cancer. This is a living cellular therapy using the patient’s own T cells and transforming them in the laboratory to fight the malignant cells. The cells More opens in new window

    F
    Falb, Robert
    Title: Director, U.S. Policy and Advocacy
    Organization: Alliance for Regenerative Medicine
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Katherine B. Szarama, PhD
    Lead Analyst
    Coverage and Analysis Group
    Centers for Medicare & Medicaid Services
    Department of Health and Human Services
    7500 Security Blvd.
    Baltimore, MD 21244 More opens in new window

    F
    Farnia, Stephanie
    Title: Director, Health Policy and Strategic Relations
    Organization: American Society for Blood and Marrow Transplantation
    Date: 06/14/2018
    Comment:

    RE: Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers
    CAG-00451N

    Ms. Syrek Jensen and Drs. Szarama and Paserchia:

    The American Society for Blood and Marrow Transplantation (ASBMT), the Center for More opens in new window

    F
    Fedderson, Stuart
    Title: Manager, Revenue Integrity
    Organization: Duke Health
    Date: 06/15/2018
    Comment:

    June 15, 2018

    Tamara Syrek Jensen, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    Katherine B. Szarama, PhD, Lead Analyst
    Evidence More opens in new window

    F
    Foss-Campbell, Betsy
    Title: Strategic Alliance Manager
    Organization: American Society of Gene & Cell Therapy
    Date: 06/15/2018
    Comment:

    Tamara Syrek Jensen, JD, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    Katherine B. Szarama, PhD, Lead Analyst
    Evidence and Analysis More opens in new window

    G
    Gatwood, Katie
    Title: Stem Cell Transplant Clinical Pharmacist
    Organization: Vanderbilt University Medical Center
    Date: 06/14/2018
    Comment:

    I have major concerns with using NCD to resolve a financial contracting issue specific to the Medicare Advantage plans, as it has such strong potential to hinder access to CAR-T for those that need the therapy. Kymriah and Yescarta are medically More opens in new window

    G
    Giralt, MD, Sergio
    Title: Chief Attending, Adult BMT Service
    Organization: Memorial Sloan Kettering Cancer Center
    Date: 06/14/2018
    Comment:

    June 13, 2018

    Ms. Seema Verma
    Administrator, Centers for Medicare & Medicaid Services
    Department of Health and Human Services
    Hubert H. Humphrey Building, Rm 445-G
    200 Independence Avenue, NW
    Washington, DC More opens in new window

    G
    Green, Sybil
    Title: Direc
    Organization: American Society of Clinical Oncology
    Date: 06/15/2018
    Comment:

    Via Electronic Submission
    June 15, 2018

    Tamara Syrek Jensen, JD, Director
    Evidence and Analysis Group
    Centers for Medicare & Medicaid Services
    7500 Security Boulevard
    Baltimore, MD 21244

    Katherine B. Szarama, More opens in new window

    G
    Gregory, Tara
    Title: Unrelated donor program director, MM program direc
    Organization: Colorado Blood Cancer Institute
    Date: 06/14/2018
    Comment:

    Re: National Coverage Analysis for Chimeric Antigen Receptor (CAR) T-cell Therapy for Cancers (CAG-00451N)

    Dear Administrator Verma, Ms. Jensen and Drs. Szarama and Paserchia:

    Colorado Blood Cancer Institute is the largest blood More opens in new window

    Page 1 of 3
    FirstPrev123NextLast
    Footer Links
    • Submit Feedback/Ask a Question
    30

    Get email updates

    Sign up to get the latest information about your choice of CMS topics in your inbox. Also, you can decide how often you want to get updates.

    CMS & HHS WEBSITES

    • Medicare.govopens in new window
    • MyMedicare.govopens in new window
    • Medicaid.govopens in new window
    • InsureKidsNow.govopens in new window
    • HealthCare.govopens in new window
    • HHS.govopens in new window

    HELPFUL LINKS

    • Acronyms
    • Archive
    • Contacts
    • Glossary
    • Privacy policy

    RSS FEEDS

    • Newsroom
    • Blog
    • Podcast
    U.S. Department of Health & Human Servicesopens in new window Centers for Medicare & Medicaid Servicesopens in new window

    A federal government website managed and paid for by the U.S. Centers for Medicare & Medicaid Services.

    7500 Security Boulevard, Baltimore, MD 21244

    opens in new window opens in new window opens in new window

    TOOLS

    • Web policiesopens in new window
    • Plain languageopens in new window
    • No Fear Actopens in new window
    • Freedom of Information Actopens in new window
    • Inspector Generalopens in new window